Protein-based COVID-19 vaccine trial launched by Sanofi and GSK

Overview

• Post By : Kumar Jeetendra


• Source: PTI


• Date: 03 Sep,2020

French drugmaker Sanofi and its British peer GSK have begun a clinical trial for a protein-based COVID-19 vaccine candidate, as pharmaceutical firms race to develop treatments against the coronavirus pandemic.

Sanofi and GSK said in a joint statement on Thursday they’d begun the”Stage 1/2″ trial for their adjuvanted COVID-19 vaccine, and that they expect to make available across the world.
This vaccine candidate utilizes the same recombinant protein-based technology as one of Sanofi’s seasonal flu vaccines with GSK’s recognized pandemic adjuvant technology.